US FDA Explains How It Is Embracing Remote Assessments Post-Pandemic

The US Food and Drug Administration on 22 July said it will keep doing remote regulatory assessments of drug manufacturing plants, clinical investigator sites and other FDA-regulated establishments, even when the COVID-19 pandemic no longer prevents travel for site inspections – and provided some insight into why.

The experience the agency developed with various types of remote assessments during the public health emergency “has identified significant benefits of using RRAs to FDA, regulated industry and the public,” the FDA